Nov 13, 2025 · Learn more about Aldeyra Therapeutics, devoted to inventing, developing, and commercializing next-generation medicines that treat immune-mediated disease.

Aldeyra cannot guarantee that the investigational product will be available to a particular patient. All decisions will be based on clinical and scientific factors that affect the benefits and risks to the …

Learn about dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, Sjögren-Larsson Syndrome, and how Aldeyra helps affected patients.

Our innovative RASP modulator platform represents a revolutionary approach to pharmacology. Unlike traditional drugs that target specific proteins, our platform targets a family of small protein-binding …

Aldeyra Therapeutics is a biotechnology company devoted to developing next-generation medicines to improve lives of patients. Learn more about us.

Immune-mediated systemic diseases, such as autoimmune disease, are generally chronic conditions characterized by excessive and misdirected inflammatory

Proliferative vitreoretinopathy is a inflammatory disorder that leads to severe retinal scarring. Learn about ADX-2191 for Proliferative Vitreoretinopathy.

In response to stimuli such as infection, injury, chemicals, and heat. Reactive Aldehyde Species (RASP) are generated through different metabolic processes that include alcohol oxidation, lipid oxidation …

Reproxalap: Our Novel Small Molecule Drug Candidate for Dry Eye By inhibiting RASP, which are elevated in a variety of inflammatory diseases, reproxalap represents a novel mechanism for …

The symptoms of allergic conjunctivitis, ocular itching & tearing, are chronic, painful and persistent. Learn about Reproxalap for allergic conjunctivitis.